Detalles de la búsqueda
1.
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
N Engl J Med
; 384(2): 105-116, 2021 01 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33185990
2.
Considerations in testing treatment effects on transient event driven health status changes measured by patient reported outcomes.
Stat Med
; 38(29): 5497-5511, 2019 12 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31631355
3.
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
N Engl J Med
; 372(16): 1500-9, 2015 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-25773607
4.
Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors.
Value Health
; 17(4): 380-9, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24968998
5.
Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
J Oncol Pharm Pract
; 20(3): 190-8, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23824496
6.
Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.
BMC Health Serv Res
; 14: 189, 2014 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24767095
7.
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
JAMA
; 311(18): 1870-82, 2014 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-24825642
8.
Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent.
Support Care Cancer
; 21(4): 987-92, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23096072
9.
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.
BMC Health Serv Res
; 13: 60, 2013 Feb 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-23406481
10.
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
JACC Heart Fail
; 8(4): 329-340, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035892
11.
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.
Eur J Heart Fail
; 22(11): 2160-2171, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32985088
12.
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.
J Cardiovasc Pharmacol Ther
; 23(5): 423-432, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29768954
13.
Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting.
Springerplus
; 5: 300, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27066336
14.
The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF).
Eur J Heart Fail
; 23(6): 1052-1056, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33826209
15.
Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?
Cancer Med
; 4(8): 1153-60, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25810005
16.
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy.
Clin Cardiol
; 37(4): 195-203, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24481874
17.
A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia.
J Med Econ
; 16(6): 720-35, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23452298
18.
Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices.
Clin Drug Investig
; 33(5): 383-9, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23553358
19.
Trends in neutropenia-related inpatient events.
J Oncol Pract
; 8(3): 149-55, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22942808
20.
Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
Med Oncol
; 29(3): 2291-9, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22081263